Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

NCT00631579 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperuricemia
Leukemia
Lymphoma

Interventions

DRUG: Rasburicase (SR29142)

Sponsor

Sanofi